Drug Type Small molecule drug |
Synonyms Rongliflozin, DJT1116PG, HEC-44616 + [1] |
Target |
Mechanism SGLT2 inhibitors(Sodium/glucose cotransporter 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
RegulationSpecial Review Project (CN) |
Molecular FormulaC28H36ClNO11 |
InChIKeyPNWMDCHPSNPLBW-JVQUDXMWSA-N |
CAS Registry2648020-91-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 2 | NDA/BLA | CN | 11 Jan 2024 | |
Diabetes Mellitus, Noninsulin-Dependent, 2 | Phase 1 | CN | 05 May 2022 | |
Liver Injury | Phase 1 | CN | 19 Apr 2022 | |
Diabetes Mellitus | Phase 1 | CN | 30 Jan 2022 |
Phase 1 | 36 | DJT1116PG 20 mg | cenmbfmzjr(rzdqrifwks) = ragnjxihpp ufvaqsxzrr (ajillmxrzs ) View more | - | 01 May 2020 | ||
DJT1116PG 50 mg | cenmbfmzjr(rzdqrifwks) = arrkrddlaq ufvaqsxzrr (ajillmxrzs ) View more |